Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

  PMID 41540108 · PMC13004696 · Nature medicine · 2026 · 7 claims · 7 setups

  Full-text index only

  GPRC5D antigenic drift/mutational events occurred in 68.4% of relapsed cases following anti-GPRC5D TCE therapy (13/19 evaluable patients)

  cd138+ pbmcs cohort bulk single-cell targeted

• Single-cell multi-omic analysis of mitochondrial mutational mosaicism and dynamics.

  PMID 41839886 · PMC12996611 · Nature communications · 2026 · 7 claims · 7 setups

  Full-text index only

  mtscATAC-seq combined with POLG D274A hypermutator HEK293 lines reveals a substantially larger single-cell mtDNA mutational burden than previously appreciated by bulk sequencing

  hek293 pbmcs mitochondrial mtdna mutational

• Tumor-specific but immunosuppressive CD39(+)CD8(+) T cells exhibit double-faceted roles in clear cell renal cell carcinoma.

  PMID 40961944 · PMC12629791 · Cell reports. Medicine · 2025 · 8 claims · 8 setups

  Has reproduction · 88

  CD39+CD8+ TILs constitute a terminally exhausted, tumor-antigen-specific subset of CD8+ T cells

  memory sorted caix-specific cd39+pd-1bright scrna-seq bulk mhc

• Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

  PMID 38897205 · PMC11293361 · Cell reports. Medicine · 2024 · 8 claims · 8 setups

  Has reproduction · 72

  Neoadjuvant sintilimab plus carboplatin/nab-paclitaxel is clinically feasible and tolerable in resectable EGFR-mutant NSCLC, with all 18 patients completing treatment and undergoing radical surgery.

  pre resected tumor serial whole-exome bulk single-cell